Oncology
| Breast Cancer
Oncology
Breast Cancer

Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results from a Randomized Trial

book_2 Source: J Clin Oncol. 2022;40(10):1051-1058.
calendar_today Published on Medfyle: June 2022
import_contacts 7 min
headphones 5 min

In this medfyle

Improved 15-year OS in early breast cancer with adjuvant capecitabine.

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Expert commentary

Valentina Guarneri, MD, PhD

University of Padova, Dept of Surgery, Oncology and Gastroenterology
Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy

About this Medfyle
Read more arrow_downward Hide arrow_upward

This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in the Journal of Clinical Oncology® (JCO), an American Society of Clinical Oncology Journal, through an official agreement with Wolters Kluwer.

The summary content was prepared by Louise Gardner for Medfyle, reviewed & approved by Prof Valentina Guarneri, MD, PhD.

Original article:
Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola A, Tanner M, Ahlgren J, Auvinen P, Lahdenperä O, Villman K, Nyandoto P, Nilsson G, Poikonen-Saksela P, Kataja V, Bono P, Junnila J, Lindman H. Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial. J Clin Oncol. 2022 Apr 1;40(10):1051-1058. doi: 10.1200/JCO.21.02054. Epub 2022 Jan 12. PMID: 35020465; PMCID: PMC8966968.

The authors of the original article had no part in the creation of the summary.

All Medfyle content, summaries, expert commentaries and slides are owned by GlobalPort (International) Limited. The original journal articles are an exclusive copyright of the American Society of Clinical Oncology.


Feedback